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Choices to be made in the regulation of medical
devices
Tomi Kauppinen
Professor, Head of Department
Department of Medical Devices  
National Agency for Medicines
Editorial
NAM’s mission statement is to promote the health
and safety of the population through the regulation
of medicinal products, medical devices and blood
products. How can medical devices be effectively
regulated where resources are limited? Where
should efforts be invested over the next few years?
For successful regulation in the medical devices sec-
tor and in order to generate the maximum benefit
for Finnish health care and patients, certain choices
must be made in the evaluation of regulatory tar-
gets.
In its inspection duties over the next few years,
the Medical Devices Department will concentrate
on high risk products, adverse incidents caused by
devices, market surveillance, and implementation
of the new legislation.
NAM has defined its strategic targets for
2008–2012. Its regulatory strategy is based on im-
pact and risk management. In the continuously
changing operational environment, there is a need
to be able to predict risks. Identification of risks is
especially important when there is a very wide vari-
ety of products to be regulated. In the medical de-
vices sector, the situation is precisely that, because
the number of products available on the market in
that sector totals around 10,000. About a third of
these are made by Finnish manufacturers.
In order to achieve the highest possible level of
safety for patients, it is necessary to focus resources
where there is significant scope to make an impact,
and a high probability of risks. In accordance with
NAM’s strategy, the regulatory and inspection ac-
tivities of the Medical Devices Department will in
future concentrate on high-risk products and on in-
creasing the number of inspections carried out. Ex-
amples of high-risk products include cardiac valves,
pacemakers, hepatitis and HIV tests and radiation
therapy and imaging devices. High risks are also
present in the various IT systems in use within
health care. Low-risk products typically include
disposable hospital accessories, plasters and clinical
thermometers.
In addition to regulation, the monitoring of
risks and of products which are the cause of ad-
verse incidents also forms an essential part of risk
management. The key tools used here include the
monitoring and evaluation of adverse incidents
caused by equipment;  this is carried out using the
adverse incidents reporting system. This reporting
system makes it possible to monitor and analyse
adverse incidents involving various product groups,
and to evaluate the risks that these present. It is
hoped that electronic reporting will lower the
threshold in terms of the decision to submit a re-
port.
The purpose of market surveillance is to oversee
the level of safety and degree of compliance with
standards of products introduced onto the market.
Choosing between different options, correct target-
ing of resources and active monitoring of markets
are also part of market surveillance. The market
surveillance programme being prepared will estab-
lish how resources are allocated in future years.
Products considered hazardous or substandard will
be withdrawn from the market in the future, too.
The Medical Devices Department is also in-
volved in the enforcing the new European legisla-
tion in Finland. A new Directive amending the Di-
rectives on medical devices and biocides was passed
by the European Parliament and the Commission
in autumn 2007. The amendments involved re-
quirements associated with, for example, compli-
ance with regulations and postmarketing monitor-
ing of devices and accessories. Medical devices in-
troduced onto the market in future will need to be
accompanied by more accurate information regard-
ing safety requirements, monitoring and instruc-
tions for use.
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In Finland, the practice and mon-
itoring of anticoagulant therapy
is decentralised and is mainly the
responsibility of those concerned
with primary health care. This
works well enough provided that
efforts are focussed on patient
guidelines and practical arrange-
ments for anticoagulant therapy.
Unfortunately, this is not always
the case in busy environments
unless the therapy is made a pri-
ority. Unlike in other European
countries and the USA, Finland
does not have centralised antico-
agulant clinics. These clinics have
been found to improve the suc-
cess of anticoagulant therapy in
both efficacy and safety, in which
case four out of five thrombotic
or five out of six haemorrhagic
complications can be avoided.
Another cost-effective practice is
anticoagulant monitoring carried
out using self-monitoring equip-
ment. With the patient taking re-
sponsibility for the treatment,
and when carried out with a sys-
tematic approach in selected pa-
tients, it decreases the mortality
by as much as 30%. Unfortu-
nately, in Finland self-monitoring
equipment can be bought by the
patient directly from a number of
department stores, in which case
there is no proof of safety with
regard to the patient’s suitability
for self-monitoring. Such equip-
ment is widely used in home
nursing, even though standard-
ised instructions for its safe and
reliable use are probably not
available. Quality monitoring of
the equipment used, sample-tak-
ing and results may be neglected.
‘Labquality’ has shown concern
about this situation and estab-
lished national guidelines for de-
veloping the overseeing of self-
monitoring equipment.
Standardisation of INR 
analyses of warfarin dosage
At a layman level one wonders
why dosage cards for warfarin
almost as a rule show daily vari-
ations of doses (e.g. 5 mg and
7.5 mg every other day). By lev-
elling out the dose (taking e.g. 6
mg every day) the patient’s mem-
ory could be improved and situa-
tions where the patient takes a
double dose or forgets to take a
dose would be avoided. Regular
uniform administration benefits
the metabolism of warfarin. Fur-
ther problems are caused by the
fact that warfarin is taken in the
afternoon and not in the morning
together with other medicines.
Administration in the afternoon
is a result of inapproriate timing
of laboratory monitoring. Moni-
toring of the INR is typically
timed to take place on the last
day of the dosage programme
even though the treatment is pre-
scribed to be long-term and often
permanent. The present practice
therefore puts the health care
centre or private operator – both
the laboratory and the doctor in
charge of the treatment – under
pressure to establish the dosage
at once. The management of INR
monitoring could be improved
by making the INR result avail-
able a couple of days before the
dosage instructions come to a
close, and by establishing the
continuation of the therapy elec-
tively rather than “acutely”. In-
ternationally, computer based
INR warfarin doses have been
found to be helpful in the man-
agement of the therapy. Further
improvement could also be seen
with a lab result service based on
electronic communication or text
messaging.
With as many as over 2% of
our population are on anticoagu-
lant therapy, mainly warfarin,
and with its use increasing by
over 10% per year, warfarin is
an increasing burden on the na-
tional healthcare system. The age
of those using warfarin is also in-
creasing especially due to the
“epidemic” of atrial fibrillation,
and hence the age of 60 years
and over is one therapeutic indi-
cation for warfarin. A 10-year
follow-up study in Cincinnati,
USA, showed that the cases of
cerebral haemorrhage caused by
warfarin increase by as much as
20% especially in the elderly
population. Based on what has
Riitta Lassila
Head of Department, Chief Specialist
Centre of excellence in coagulation disorders 
Haematology Department and HUSLAB, Helsinki
University Central Hospital, Meilahti Hospital
National collaborative effort for anticoagulant
therapy
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been said above, it is recommend-
ed that management of warfarin
therapy in Finland be tailored
with guidelines.
Warfarin has the largest 
number of harmful drug 
interactions
It is doubtful whether warfarin
would get marketing authorisa-
tion nowadays because of its nu-
merous difficult properties. War-
farin causes the largest number of
adverse drug reactions. According
to international studies, severe
haemorrhages occur in at least
2–3% of patients on anticoagu-
lant therapy every year. Warfarin
tops the list of adverse drug reac-
tions occurring in Finland. The
most common cases of haemor-
rhage as an adverse drug reaction
are associated with the combined
use of warfarin and anti-inflam-
matory analgesics, some antibi-
otics and some antifungals (in-
cluding the topical administra-
tion).
The problems with warfarin
are caused by its vitamin K de-
pendent mechanism of action and
the CYP2C9 route of metabo-
lism, and severe drug interac-
tions. A classic case is developed
when an infection and associated
antibiotic treatment are involved,
in which case for example the in-
fection on the one hand increases
the levels of fibrinogen and Fac-
tor VIII and may intensify the
need for warfarin. On the other
hand, antibiotic treatment affects
the absorption of vitamin K and
may cause direct drug interac-
tions (e.g. with metronidazole,
which potentiates the effect of
warfarin). Acute and chronic in-
flammatory bowel diseases are al-
so very complicated. A couple of
studies published recently show
that a regular consumption of vit-
amin K (the daily requirement is
0.1 mg) puts the reaching of the
INR target in balance in patients
whose balance of treatment is
otherwise difficult to keep under
control. More appropriate
strengths would also be needed
both for warfarin and vitamin K,
e.g. a tablet of 1 mg of warfarin
and tablets of 0.1 mg and 1 mg
of vitamin K.
Cancer patients and invasive
measures
All major changes in the adjust-
ment of drug therapy are harmful
unless the patient is knowingly
being transferred to small molec-
ular heparin injection therapy.
This is the recommended proce-
dure for a period of at least 6
months in the treatment of deep
vein thrombosis in cancer pa-
tients. Irrespective of warfarin,
deep vein thrombosis may occur
in as many as 10% of cancer pa-
tients. Treatment for cancer with
associated cytostatic treatment al-
so exposes the patient to cytopae-
nia and, as a result of radiothera-
py and surgery, also to tissue
damage. These conditions are dif-
ficult to treat in association with
warfarin therapy.
Low-molecular-weight heparin
is also used in bridging therapy,
i.e. in association with major
surgery. For this purpose, treat-
ment units should have clear al-
gorithms for the readjustment of
anticoagulant therapy, not to
mention suppression of treat-
ment, when the indication for
surgery is haemorrhage caused by
warfarin. With this in mind, two
prothrombin compounds (Cofact
and Octaplex) with immediate
suppressive effect on warfarin
have recently been registered in
Finland. In emergency situations,
e.g. severe haemorrhage or emer-
gency operation, these will be
used to restore the clotting sys-
tem (Table and Fig. 1).
Pharmacogenetics of warfarin
The individual dose of warfarin
therapy varies within a 20-fold
range. New pharmacogenetic
tools are available (HUSLAB, B-
VarfaD) for making the introduc-
tion of warfarin therapy easier.
Polymorphism of CYP2C9 and
Doses to cut warfarin therapy by using two 
alternative products when INR is above 3.0.
Weight of      Cofact Octaplex
patient
40–60 kg            30–60 ml 1500 IU
60–90 kg            60–80 ml 2000 IU
over 90 kg          80–100 ml 2500 IU
h h
Vitamin K
Fig 1. Cutting down on the dose of warfarin in association with severe
haemorrhage and procedures which require good haemostasis. Pro-
thrombin complex concentrates (PCC) and vitamin K are administered
immediately, and as the effect of PCC diminishes synthesis of the coagu-
lation factors themselves will start.
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VKORC1 explain about 50% of
the individual dose requirement.
For the pharmacogenetic individ-
ual administration there is an al-
gorithm model at the following
website: www.warfarindosing.
org. As a result of some rare
(1–3%) polymorphisms of
CYP2C9 the dose requirement is
minimal and the elimination sig-
nificantly reduced; pharmacoge-
netic information detects an indi-
vidual prone to haemorrhage and
will also help in the targeting of
other medication metabolised via
CYP2C9. Experience should be
gained from this new option, and
the experience should be brought
into proportion with the other
factors affecting the patient’s
proneness to thrombosis and
haemorrhage. The most common
of these are probably the use of
anti-inflammatory analgesics,
which impair the haemostasis,
and hypertension which has been
left untreated or is out of control.
Both of these expose the warfarin
user to cerebral haemorrhage. I
believe that the biggest benefit to
start with could be obtained in
such patients as are suspected of
being at risk of haemorrhage and
who have in a year haemorrhages
more than 10% of which are se-
vere (a high bleeding risk index).  
Anything else new in sight?
Extensive efforts have been un-
dertaken to develop new alterna-
tive options to warfarin, and
there are some within sight in
fact – e.g. dabigatran, a direct in-
hibitor of thrombin, and rivarox-
aban, a direct inhibitor of the
clotting factor Xa (Fig. 2). These
oral anticoagulants will apparent-
ly be introduced to the market
for short-term prophylaxis of
thrombosis as early as this year.
However, it will still take years
before they are in long-term use,
or before they are at least used in
the treatment of patients with an
artificial cardiac valve. The new
drugs have shown antithrombotic
efficacy, but the safety of their
use will not be established until
extensive series of patients and
long monitoring periods (a mini-
mum of 18 months) have been
gone through. The first direct
thrombin inhibitor, ximelagatran,
was unfortunately withdrawn
from the market immediately be-
fore it was due to take the role of
warfarin. The reason for the
withdrawal was the elevation of
liver enzymes detected on long-
term monitoring and found in
6–9% of the patients treated.
Conclusion
The circumstances described
above are a clear indication that
there is a need for monitoring the
anticoagulant therapy given, for
patient guidelines and for a versa-
tile development. In countries
where there are anticoagulation
clinics the safety of use and effi-
cacy of anticoagulant therapies
have been shown to be distinctly
superior in comparison with the
decentralised model. The impor-
tance of patient guidelines of high
quality is emphasised. As air trav-
el is becoming more and more
common patients on warfarin
therapy need to prepare them-
selves for the journey, and possi-
bly even for INR monitoring be-
fore the return journey as well,
since diet and drinking habits
probably change while away
from home. Patient guidelines in-
clude, for example, information
about the International Self-mon-
itoring Association of oral Anti-
coagulated Patients (ISMAAP),
an organisation concentrating on
patient guidelines. Its present
chairman is an internationally
renowned researcher on blood
coagulation, and this reflects the
significant emphasis on patient
guidelines.
INR monitoring and dosage
adjustment carried out by pa-
tients themselves using self-moni-
toring equipment increases the
safety of anticoagulant therapy.
With careful patient selection,
systematic teaching programme,
and the monitoring of equipment
and quality, mortality associated
with warfarin therapy has been
shown to decrease. The responsi-
bility of ‘Labquality’ includes is-
sues related to the quality moni-
toring of the screened introduc-
tion and follow-up of self-moni-
toring equipment. All parties in-
terested in safe medical treatment
and improved quality in health-
care in Finland should quickly
join forces. Safety of warfarin
therapy requires national recom-
mendations and centralised ef-
forts.
Fig. 2. The coagulation system and relevant anticoagulants.
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International studies have shown
that 5 to 10% of patients at some
time of their treatment experience
some unwanted or unforeseen
event which may harm them (5).
A high proportion of errors in
the patient’s treatment are caused
by errors in medication.
A medication error is an
event, associated with drug thera-
py, which can lead to a hazar-
dous situation. It may be caused
by an action, failure to act, or a
situation where the protective
measures have failed (6). It is an
event which can be prevented,
but which, if it is not, can lead to
medication which is inappropri-
ate or harmful to the patient, in
which case the responsibility for
the administration lies with a
healthcare professional, a patient
or some other consumer (7).
About 1% of the patients are as-
sailed by a severe adverse reac-
tion as a result of the irregularity
(8, 9). 
Special care is required in the
administration of medicinal prod-
ucts associated with a risk to the
patient of a severe adverse reac-
tion: these are known as high
alert medications, since their stor-
age, labelling, reconstitution or
administration to the patient re-
quire exceptionally good care
(10). 
In this study information has
been compiled concerning the
practices in recording of medica-
tion errors in central hospitals,
and the views of hospital phar-
macists on guidelines relating to
high alert medications have also
been examined. The study has
been based on a list of high alert
medications assembled up by the
American Institute for Safe Med-
ication Practices (ISMP). The list
has been updated in 2007.  
Procedures
Hospital pharmacists (n=21) in
Finnish central hospitals were
sent a survey questionnaire by
email in the spring of 2006. Phar-
macists were asked about the pre-
vailing practices in their own hos-
pitals with regard to guidelines
and the supervised use of high
alert medications. The regulations
and practices associated with
these medications were also scru-
tinised by way of a Table follow-
ing the ISMP style (Tables 2 and
3). The survey was completed by
11 hospital pharmacists (response
rate of 52%).   
Results 
Monitoring of medication errors? 
Active monitoring of medication
errors took place in three hospi-
tals and two hospital pharmacies.
The monitoring was carried out
by using reports (n=2), adverse
drug reaction reports (n=1) or
other ways specific to the individ-
ual department (n=1). In addition
to monitoring, an extensive elec-
tronic patient record system was
going to be introduced at one of
the hospitals.       
Prevention of medication errors?
The various measures taken to
prevent medication errors were
described in eight replies (Table
1). The most common measures
included setting up of guidelines
for the medication practice, pro-
viding information about any
changes in the range of medicinal
products available, and furnish-
ing guidelines for nurses about
how to recognise generic medici-
nal products. Difficulties were
found to arise in the recognition
of generic medicinal products in
patient care, for example when
patients were hospitalised. Mea-
sures to improve the safety of
medication have been introduced
in two hospitals.
Monitoring of high alert medications?
When asked about specific means
for the monitoring of medicinal
products, five hospital pharma-
cists replied that they did not
have in place monitoring focusing
on medication risks of the prod-
ucts, and that all medicinal prod-
ucts were monitored equally. The
Guidelines for the use of high alert medications
and monitoring of medication errors in hospitals
Sanna Pohjanheimo
B.Sc. (Pharm.)
Division of Social Pharmacy 
University of Helsinki
Marja Airaksinen
Professor
Division of Social Pharmacy 
University of Helsinki
Carita Lindén
M.Sc. (Pharm.)
Palmenia Centre for Continuing Education
University of Helsinki
Teressa Lyly
M.Sc. (Agriculture), B.Sc. (Pharm.)
Division of Social Pharmacy 
University of Helsinki
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list of high alert medications was
filled in by five hospital pharma-
cists (Tables 2 and 3).
Appropriateness of the ISMP list of
high alert medications?
The question about the appropri-
ateness of the list of high alert
medications in Finnish hospitals
received five replies. A couple of
the medicinal products in the list
were not considered high alert
medications by the hospital phar-
macists, and in the case of a cou-
ple of others the risk of medica-
tion errors was in their opinion
also considerably higher. The
medicinal products most com-
monly considered high alert med-
ications included adrenergic ago-
nists, parenteral and chemothera-
peutic substances, inotropic med-
icines, epidural or intrathecal
drugs, the liposomal medicinal
substances, anaesthetics and opi-
oids, muscle relaxants, intravas-
cular radioactive imaging prod-
ucts and thrombolytics/fibrinolyt-
ics. The medicinal products most
definitively considered high alert
medications included lidocaine,
potassium chloride concentrate,
potassium phosphates injection,
sodium chloride for injection, hy-
pertonic and warfarin. However,
dialysis solutions, intravascular
sedative medication or oral seda-
tive medication for children were
not considered high alert medica-
tions (Tables 2 and 3).
The aim of an open question
to the participants in the survey
was to explore the participants’
views on the hazardous proper-
ties of various drugs. In two
replies the list of high alert med-
ications used in the study was
considered too long. It was nev-
ertheless suggested that botu-
linum toxin, antitoxins and anti-
dotes be included in the list. In
one open reply it was also main-
tained that any specific instruc-
tions given on the wards are not
always effectively communicated
to the hospital pharmacy, nor
does the pharmacy know about
all near misses occurring with
medications.
Conclusions
Medication errors were not sys-
tematically monitored in Finnish
central hospitals in spring 2006.
The conventional record form
was found to be a sufficiently
good way of recording any med-
ication errors (1, 2, 3, 4). The
record is easily converted into
electronic form and is appropri-
ate to use for the recording of
medication errors and for moni-
toring of hospital practices.
A process of reporting haz-
ardous events, HaiPro, in order
to promote patient safety issues
Table 1. Prevention of medication errors in central hospitals (n=8).
Procedure n
Guidelines for the practice 3
Communication about changes in the range of drugs available 3
Recognition and review of a generic drug 3
Making use of ward pharmacy 2
Pharmaceutical education for hospital staff 2
Responses to medication errors and near misses 1
New practice being introduced 2
Medication error is any preventable event which can cause or lead to inappropriate use of a medicinal 
product or harm the patient when responsibility of the administration lies with a healthcare professional, 
or a patient or other consumer.
High alert medications are medicinal products conventionally used in medical therapies, but which, when
incorrectly administered, expose the patient to inordinately more severe health hazards.
Our study shows that hazards caused by high alert medications can be prevented by taking a number of
measures, including for example the extensive use of information technology, increasing the use of ward
pharmacies, and developing multi-professional forms of working and methods of medication.
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Table 2. The views of hospital pharmacists on high alert medications (n=5, x=one reply). The replies are compiled into an ISMP list of high alert  
medications (12).  The list has been updated 2007.
Medicinal substance
Does this group of medicinal substances 
belong to the high alert medications in 
your opinion? 
Does your hospital have special instructions for the storage or 
labelling of this group of medicinal substances?
Yes No Yes No
Storage      Labelling
Adrenergic agonists, intravenous
(e.g. adrenalin) XXXXX XX XX
Adrenergic antagonists, 
intravenous (e.g. propranolol) XX XXX XXX
Anaesthetic agents in general, 
inhaled and intravenous XXX XX XXX
Chemotherapeutic agents, 
parenteral and oral XXXXX XX XXX X
Hypoglycaemic oral XX XXX XXX
Inotropic medication
(e.g. digoxin) XXXXX XXX
Cardioplegic solutions XXX XX XXX
Hypertonic dextrose solution 
(>20 %) XXX XX XXX
Dialysis solutions X XXXX XXX
Epidural or intrathecal 
medications XXXX X XXX
Glycoprotein IIb/IIIa inhibitors 
(e.g. abciximab) XXX XX XXX
Liposomal formulation of drugs 
(e.g. amphotericin B) XXXX X XXX
Moderate sedation agents, 
intravenous
X XXXX XXX
Moderate sedation agents,
oral, for children X XXXX XXX
Narcotics/opiates, intravenous 
and oral XXXX X X X XXX
Neuromuscular blocking agents
XXXX X XXX
Radiocontrast agents, 
intravenous XXXX X XX XX XX
Thrombolytics /fibrinolytics, 
intravenous 
XXXX X XXX
Parenteral nutritional solutions XX XXX XX X XX
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has already been developed in
Finland (13). Setting up of multi-
professional working groups at
hospitals would also be ideal;
such working groups would regu-
larly analyse any problem situa-
tions recorded and develop the
general safety of medicines.   
If the hospital pharmacy is not
informed about problems associ-
ated with medications on wards,
it is not able to respond to the
problems. By using the ward
pharmacy or by the setting up of
multi-professional working
groups in support of patient care,
the expertise of the hospital phar-
macy could be brought into prac-
tice and the safety of medicinal
products be improved.    
Shortage of time is a big prob-
lem in the work of nurses and
pharmacy staff. Improving the
standard operating procedure
(SOP) could probably reduce the
workload in patient care and the
diversity of the codes. With ward
pharmacies the responsibility for
the reconstitution of medicines
and preparing them for use could
become the responsibility of the
pharmacist. Increasing the prac-
tice of ward pharmacies could al-
so achieve harmonisation of SOP
on wards, a reduction in the
workload of nurses and an in-
crease in the expertise on medi-
cines among the nursing staff.
In order to improve the safety
of medication in Finland, a list of
high alert medications appropri-
ate for our practices could be
compiled; it would make use of
the expertise of hospital pharma-
cies as well as information re-
ceived from hospitals about any
medication errors, as well as
from the National Board of
Medicolegal Affairs (17) and
about cases of patient injuries.
Literature: see page 15.
Table 3. The views of hospital pharmacists on high alert medications (n=5, x=one reply). 
The replies are compiled into an ISMP list of high alert medications (12). The list has been 
updated 2007.
Medicinal substance
Is this medicinal 
substance a high alert
medication in your 
opinion? 
Does your hospital have special instructions
for storage or labelling of this medicinal 
substance? 
Yes No Yes No
Storage Labelling
Amiodarone
intravenous
xx xxx xxx
Colchicine injection xxx xx xxx
Heparin in injection 
form, low-molecular-
weight
xx xxx xxx
Heparin, intravenous, 
unfractionated
xx xxx xxx
Insulin, intravenous 
and subcutaneous
xx xxx xxx
Lidocaine, 
intravenous
xxxx x xxx
Magnesium sulphate 
injection
xxx xx xxx
Methotrexate, oral 
non-oncologic use 
xxx xx xx xx xx
Nesiritide x xxxx xxx
Nitroprusside sodium 
for injection 
xxx xx x xxx
Potassium chloride for
injection concentrate
xxxxx xxx
Potassium 
phosphates injection
xxxxx xx
Sodium chloride for
injection, hypertonic
xxxx x xx
Warfarin xxxxx x xx
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The 1 174 reports included alto-
gether 2 568 ADR symptoms,
which means in average 2,4
ADRs for report. ADRs reported
on vaccines are not included in
this review.
Altogether reports were re-
ceived for 348 medicinal sub-
stances. From 214 medicinal sub-
stances there were two or less re-
ports. The medicinal substances
for which 10 or more reports
were received are listed in Table
2. New medicinal substances on
this list are varenicline (Champix)
used for smoking cessation, ari-
piprazole (Abilify) used for the
treatment of schizophrenia,
buprenorphine-naloxone (Subox-
one) used as substitution treat-
ment for opiod drug dependence
as well as rimonabant (Acomplia)
used for the treatment of obesity.
Varenicline, buprenorphine-
naloxone and rimonabant have
been granted marketing authori-
sations within the past two years,
although buprenorphine-nalox-
one has been available before
that trough named patient use.
Escitalopram (Cipralex, marketed
since 2003) is also a newcomer
on the list of most frequently re-
ported medicinal substances.
Well-known medicinal substances
nitrofurantoin (Nitrofur-C) is
back on the list with it’s pul-
monary ADRs. Infliximab, which
is used for the treatment of e.g.
rheumatoid arthritis, inflammato-
ry bowel diseases and psoriasis, is
now on the second place on this
list. The number of ADR reports
regarding infliximab doubled
during last year, while the con-
sumption also has increased year
by year. On the third place is
clozapine which has been on the
fifth place on the lowest during
the last 10 years.
Most of the reports received
concerned medicines from the
ATC-classifications Nervous sys-
tem (N), Antineoplastic and im-
munomodulating agents (L) and
Cardiovascular system (C).
The reported ADRs are coded
with MedDRA (Medical Dictio-
nary for Regulatory Activities).
Most of the reports included
ADRs from the system organ
class (SOC) General disorders
and administration site condi-
tions. It was followed by ADRs
from SOCs Gastrointestinal dis-
orders, Skin and subcutaneous
tissue disorders and Nervous sys-
tem disorders. Most often report-
ed individual ADR was rash (88),
followed by urticaria (74), hepat-
ic function test abnormalities
(66), allergic or anaphylactic re-
action (63) and decreased white
blood cell count i.e. leukopenia
of various severity.
Safety of medicinal substances
cannot be compared with one an-
other on the basis of the number
of ADR reports. There is substan-
tial variation in the consumption
of the listed medicinal substances,
and ADRs are reported more of-
ten from medicinal substances
that frequently used than for
those less commonly used. In ad-
dition, the reporting activity can
be influenced by for example me-
dia visibility of a certain drug
safety issue, or by the recommen-
dation by NAM to report espe-
cially serious ADRs, suspected in-
teractions, unexpected ADRs or
suspected ADRs of medicinal
substances that have been on the
market for less that two years, or
if the reporter feels that the fre-
quency of a certain ADR appears
to have increased.
Adverse reactions in year 2007 in Finland
Tiina Karonen
Senior Medical Officer
National Agency for Medicines
Leena Sommarberg
Reseacher
National Agency for Medicines
Table 1. Criteria of serious ADR:
• resulted in death
• was life-threatening
• caused/prolonged hospitalisation
• caused disabling/incapacitating defect
• caused congenital anomaly/birth defect
Last year the National Agency for Medicines (NAM) in Finland received altogether 1 174 reports of
suspected adverse drug reactions (ADRs), which was slightly more than the year before. There was
some alteration in the list of most often reported medicinal substances, but the spectrum of the 
reported ADRs was greatly similar to the earlier years. 753 (64 %) reports were classified as serious
(criteria Table 1), which was a greater percentage than before.
TABU 2. 200854
In English
Contrast media
Altogether 59 reports concerning
iodine-containing contrast media
were received and 47 of these
concerned iomeprol (Iomeron).
Most of the reports were received
from the same district, reflecting
similar local reporting activity as
was seen the previous year. The
reports received most often in-
cluded urticaria (24), vomiting
and/or nausea (25), or other al-
lergic symptoms like dyspnoea or
swelling of mouth or throat. Ana-
phylactic reaction or shock was
reported four times, of which two
from iomeprol. No reports with
fatal outcome were received.
Selective immunosuppressive
agents and methotrexate
Most of the reports received from
tumour necrosis factor alpha
(TNF-alpha) inhibitors concerned
infliximab, which has been the
longest on the market in Finland
from this therapy group. Most of
the reports concerned anaphylax-
is or allergic reaction (7), or mis-
cellaneous symptoms related to
those (11), infusion-related symp-
toms (10) or various infections
(10). These reflect the nature of
the product (monoclonal anti-
body), its mechanism of action
and the intravenous administra-
tion route.
Etanersept (Enbrel) belongs to
the similar therapy group and is a
fusion protein that competitively
inhibits the binding of TNF-alpha
to the surface receptors of cells. It
is administered as subcutaneous
injections, and the indications for
use include rheumatoid arthritis,
psoriatic arthritis and plaque pso-
riasis. Altogether 16 reports from
infliximab were received: injec-
tion site reactions were described
in three and dermatological
symptoms in five. In addition one
case of lymphoma and two infec-
tions were reported, including tu-
berculous peritonitis and viral en-
cephalitis.
Adalimumab (Humira) is also
a monoclonal antibody that
specifically binds to TNF. It is
used in the treatment of for ex-
ample rheumatoid arthritis,
Crohn’s disease and psoriasis. Al-
together 12 reports of adalimum-
ab were received, including two
reports of tuberculosis.
When treating rheumatoid
arthritis all the above medicinal
substances are primarily used in
combination with methotrexate.
Altogether 12 reports concerning
methotrexate were received, four
of which concerned hepatic
ADRs, three pulmonary disorders
and one progressive multifocal
leukoencephalopathy.
Antipsychotics
While clozapine was the most of-
ten reported, also reports from
other antipsychotics were received:
22 reports of quetiapine (Seroquel,
Ketipinor), 18 of aripiprazole and
13 of risperidone. Most of the re-
ports concerning clozapine includ-
ed leukopenia of various serious-
ness (24), and in addition on peri-
carditis were reported (3).
Aripiprazole has been on the
market for the treatment of schiz-
ophrenia since 2004, and during
2007 the use of it almost doubled
when compared to the previous
year. Most of the reported ADRs
were neurological symptoms like
extrapyramidal movement disor-
ders and tardive dyskinesia (3 al-
together) as well as neuroleptic
malignant syndrome (3). In addi-
tion gastrointestinal symptoms
(5), various psychiatric behaviour
disorders (4), one of which was
suicide attempt, and leukopenias
(3) were reported.
Neuroleptic malignant syn-
drome was reported twice also
related with the use of quetiap-
ine. In addition tardive dyskinesia
(2) and other neurological symp-
toms (7) were reported for queti-
apine. The most often reported
ADRs for risperidone were also
various neurological movement
disorders (8) and neuroleptic ma-
lignant syndrome (2).
Antidepressants
Duloxetine (Cymbalta) has been
on the market since 2005, and
most of the ADRs reported were
neurological (16) and psychiatric
(14), including e.g. dizziness and
balance disorders (6), as well as
Table 2. The medicinal substances most
frequently reported in 2007.
iomeprol 47
infliximab 46
clozapine 38
pregabalin 34
duloxetine 30
simvastatin 29
varenicline 23
terbinafine 22
quetiapine 22
etonogestrel-ethinylestradiol 20
etoricoxib 19
aripiprazole 18
levofloxacin 16
etanercept 16
levonorgestrel (IUD) 14
mirtazapine 14
risperidone 13
fluvastatin 12
drosperidone-ethinylestradiol 12
nitrofurantoin 12
capecitabine 12
bevacizumab 12
adalimumab 12
methotrexate 12
buprenorphine-naloxone 11
rimonabant 10
rituximab 10
escitalopram 10
venlafaxine 10
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suicidal thoughts or suicide at-
tempt (3). Also various gastroin-
testinal ADRs were described in
10 reports. In addition to depres-
sion other indications for duloxe-
tine use are the treatment of pe-
ripheral diabetic neuropatic pain
and female stress urinary inconti-
nence. 
Altogether 14 reports were re-
ceived on mirtazapine, including
e.g neurological symptoms (11)
like restless legs and muscle
twitching, as well as dermatolog-
ical symptoms (4).
Ten reports were received for
both venlafaxine (Efexor depot)
and escitalopram. In the case of
escitalopram, 3 reports concer-
ned suicide or suicide attempt.
Suicidal thoughts were reported
in one case related with use of
venlafaxine. In addition, various
cardiovascular ADRs were re-
ported, including palpitations,
tachycardia or high or low blood
pressure.
The Committee of Human
Medicinal Products (CHMP) of
the EMEA has performed a class
review of antidepressants and the
risk of suicide among young
adult patients. The summaries of
product characteristics (SPC) and
packet leaflets (PL) of antidepres-
sants are further specified on this
issuer during this spring.
Pregabalin
GABA analogue pregabalin (Lyri-
ca) was introduced to the Finnish
market in 2004 for the treatment
of neuropatic pain, epilepsy and
later on for generalised anxiety
disorders. It’s use has increased
almost 50 % every year. In great
majority of the 34 reports re-
ceived last year the indication for
use was (neuropatic) pain. As
during the years before, majority
of the reported ADRs were psy-
Eye disorders
2 %
Pregnancy, puerperium
and perinatal conditions
2 %
Vascular disorders
2 %
Immune system disorders
3 %
Hepato-biliary disorders
3 %
Injury and poisoning
3 %
Infections and
infestations
3 %
Cardiac disorders
3 %
Psychiatric disorders
5 %
Respiratory, thoracic and
mediastinal disorders
7 %
Musculoskeletal,
connective tissue and
bone disorders
5 %
Blood and lymphatic
system disorder
4 %
Others
5 %
Investigations
8 %
Nervous system disorders
11 %
Renal and urinary
disorders
2 %
General disorders and
administration site
conditions
12 %
Gastrointestinal disorders
11 %
Skin and subcutaneous
tissue disorders
11 %
chiatric and neurological symp-
toms. In addition various general
symptoms were reported, includ-
ing feeling hot and oedema (5 of
each).
Statins
The reimbursement practice of
statins changed in Finland during
the last part of year 2006, and
the consumption of simvastatin
increased over 50 % during 2007
when compared to the previous
year. Also the number of ADRs
reported for simvastatin in-
creased. The reported ADRs
were mostly known and affected
the muscles: rhabdomyolysis (4),
myalgia and muscle cramps or
increased creatine kinase (CK)
levels (altogether 8). In addition
various dermatological ADRs (5)
and hepatic failure (2) were re-
ported.
The consumption of fluvas-
tatin increased by a quarter com-
pared to the previous year. For
the other statins the use de-
creased. The reported ADRs
were mostly similar to the above:
increased CK and hepatic en-
zyme levels.
Medicines used in addictive
disorders
Varenicline, which is used for
smoking cessation, was granted
marketing authorisation trough
the centralised procedure in Sep-
tember 2006, and thus most of
the usage experience has cumu-
lated during last year. The
CHMP also assessed the safety
of varenicline last year, especially
regarding psychiatric ADRs and
suicidal thoughts, and the SPCs
and PLs will be completed dur-
ing this spring.
The ADRs reported to NAM
on varenicline most often con-
cerned nausea and other gas-
trointestinal symptoms (10), der-
matological symptoms (8), mus-
cle cramps or myalgia (5) and
various general symptoms like
oedema or tiredness (4 of each).
Fig. Reported adverse drug reactions (n=2 568) according to SOCs 
in 2007.
Altogether 8 psychiatric ADRs
were reported: 2 of them con-
cerned mania or psychosis, 3
sleeping difficulties and the rest
isolated psychiatric symptoms.
There were no reports of suicidal
thoughts during year 2007; some
have been received during 2008.
Buprenorphine-naloxone is a
combination product; buprenor-
phine binds slowly and reversibly
to the myy-opioid receptors in
the brain. Naloxone is an antago-
nist of the same receptor type,
and when given orally to patients
experiencing withdrawal symp-
toms it has minimal pharmaco-
logical effect, but when adminis-
tered intravenously it causes no-
table antagonist effect and with-
drawal symptoms, thus prevent-
ing intravenous abuse. 
The consumption of buprenor-
phine-naloxone has increased
evenly, without any remarkable
peak in 2007, at the end of which
Subutex, which contains only
buprenorphine, remained avail-
able only trough named patient
use for pregnant patients. 
All the 11 reports received ar-
rived during the same week and
concerned various symptoms of
teeth, including tooth pain, tooth
loss and erosion. In all the cases
the original report was completed
by the patient himself at the pres-
ence of a nurse, who then had
submitted the reports to the mar-
keting authorisation holder, after
having herself seen the conditions
of the patients’ teeth. Further in-
formation was requested from the
treating physician(s), but the pre-
vious condition of the patients’
teeth was not familiar to the
physician. No clear causal rela-
tionship between the symptoms
and the treatment was suspected
at this point.
Coxibs
Rofecoxib was withdrawn from
the market on 2004 due to seri-
ous thrombotic cardiovascular
events. This action was followed
by a class review of the other
coxibs, and in 2005 the market-
ing authorisation (MA) of valde-
coxib was suspended due to seri-
ous dermatological ADRs. The
latest recommendation from the
CHMP was on 2007 to withdraw
the marketing authorisations of
lumiracoxib due to serious hepat-
ic ADRs.
There are two orally adminis-
tered coxibs still in use in Fin-
land: celecoxib (Celebra) which
was granted the MA in 2000 and
etoricoxib (Arcoxia) since 2002.
The consumption of celecoxib
has decreased slightly year by
year, whereas that of etoricoxib
has increased. When compared to
the defined daily dose (DDD)-es-
timates the use of etoricoxib was
on the same level as that of di-
clofenac and ketoprofen, regard-
less of the news on coxibs and
the more limited indication.
ADRs related to etoricoxib
were reported in 19 reports.
Most of them concerned gastroin-
testinal or dermatological symp-
toms (5 of each). Cardiovascular
or hepatic ADRS were reported
twice. Dermatological symptoms
in connection to celecoxib use
were reported twice.
Contraceptives
Nuvaring contraceptive vaginal
ring (etonorgestrel-ethinylestra-
diol) was reported 20 times, 15
of which concerned unintended
pregnancy, one extra uterine
pregnancy, one deep venous
thrombosis and one pulmonary
embolism. All the 14 reports of
levonorgestrel concerned Mirena,
a hormonal IUD. Unintended or
extra uterine pregnancy was de-
scribed in four reports. The
ADRs described in the rest of the
reports were various. In addition,
12 reports of drospirenone-
ethinylestradiol (11 Yasmin, 1
Yasminelle) were received. Unin-
tended pregnancy was reported in
four of these, cerebral infarction
in two and pulmonary embolism
in one of these reports.
Antineoplastic agents
Vascular endothelial growth fac-
tor (VEGF) inhibitor bevacizum-
ab was reported 14 times and 5-
fluorouracil precursor capeci-
tabine 13 times. The patients de-
scribed in these reports were of-
ten in poor condition to start
with due to the background dis-
ease. A few neutropenic infec-
tions and cardiovascular symp-
toms were reported in connection
to capecitabine. Various ADRs
were reported for bevacizumab,
including e.g. intestinal perfora-
tion, cerebral infarction, hemi-
paresis and paraparesis.
Rimonabant
Rimonabant is used for the treat-
ment of obesity and affects the
endocannabinoid system. It was
granted marketing authorisation
in 2006. Last year 10 ADR re-
ports were received, including
various events. Depression or ap-
athy was described in three re-
ports. During summer 2007
CHMP concluded that the warn-
ing regarding depression in the
SPC was to be changed to be-
come a contraindication of treat-
ment.
Conclusion
NAM wishes to thank all health
care professional for reporting
ADRs. Spontaneous reporting is
important because especially rare
ADRs can be detected only after
wider use and when different pa-
tient populations are treated. A
suspected ADR is worth report-
ing especially if it is serious, un-
expected or the suspected drug is
new and has been on the market
less than two years.
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